High-throughput microRNA profile in adult and pediatric primary glioblastomas: the role of miR-10b-5p and miR-630 in the tumor aggressiveness

Darrigo, Luiz Guilherme; Baroni, Mirella; Lira, Régia Caroline Peixoto; Teixeira, Silvia A.; Fedatto, Paola Fernanda; Silveira, Vanessa da Silva; Suazo, Veridiana Kill; Veronez, Luciana Chain; Panepucci, Rodrigo Alexandre; Antônio, David Santos Marco; Yunes, José Andrés; Brandalise, Sílvia Regina; Aguiar, Simone dos Santos; Neder, Luciano; Oliveira, Ricardo Santos de; Machado, Hélio Rubens; Carlotti, Carlos Gilberto; Tone, Luíz Gonzaga; Valera, Elvis Terci; Scrideli, Carlos Alberto

doi:10.1007/s11033-020-05754-3

Cited by 7 publications

(9 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…RNA integrity was evaluated on a 2100 Bioanalyzer (Agilent). miRNA expression profiling was generated by using the Human miRNA Microarray kit (V3), 8 × 15K (based on Sanger miRbase release 12.0, G4470C, Agilent Technologies, Santa Clara, CA, USA), as previously reported 22 . The quantile normalization was performed by using R/Bioconductor‐package preprocessCore, 23 which forces sample distributions to be equal on the basis of the sample quantiles, replacing each point in a sample with the mean of the corresponding quantile 23 .…”

Section: Methodsmentioning

confidence: 99%

“…miRNA expression profiling was generated by using the Human miRNA Microarray kit (V3), 8 × 15K (based on Sanger miRbase release 12.0, G4470C, Agilent Technologies, Santa Clara, CA, USA), as previously reported. 22 The quantile normalization was performed by using R/Bioconductor-package preprocessCore, 23 which forces sample dis-tributions to be equal on the basis of the sample quantiles, replacing each point in a sample with the mean of the corresponding quantile. 23 The identification of differentially expressed miRNAs between the NNA and ACT samples was performed by using the Limma R package, considering as a cutoff a log fold change (FC) above 1.5 or below −1.5 and adjusted p-value <.01.…”

Section: Microarray-based Mirna Profiling and Analysismentioning

confidence: 99%

See 1 more Smart Citation

MicroRNA expression profile predicts prognosis of pediatric adrenocortical tumors

Veronez

Fedatto

Corrêa

et al. 2021

Pediatric Blood & Cancer

Self Cite

View full text Add to dashboard Cite

Pediatric adrenocortical tumors (ACT) are rare aggressive neoplasms with heterogeneous prognosis. Despite extensive efforts, identifying reliable prognostic factors for pediatric patients with ACT remains a challenge. MicroRNA (miRNA) signatures have been associated with cancer diagnosis, treatment response, and prognosis of several types of cancer. However, the role of miRNAs has been poorly explored in pediatric ACT. In this study, we performed miRNA microarray profiling on a cohort of 37 pediatric ACT and nine nonneoplastic adrenal (NNA) samples and evaluated the prognostic significance of abnormally expressed miRNAs using Kaplan-Meier plots, log-rank test, and Cox regression analysis. We identified a total of 98 abnormally expressed miRNAs; their expression profile discriminated ACT from NNAs. Among the 98 deregulated miRNAs, 17 presented significant associations with patients' survival. In addition, higher expression levels of hsa-miR-

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Microarray-based Mirna Profiling and Analysismentioning

confidence: 99%

MicroRNA expression profile predicts prognosis of pediatric adrenocortical tumors

Veronez

Fedatto

Corrêa

et al. 2021

Pediatric Blood & Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

“…A total of 24 primary MB samples (19 pediatric and 5 adult specimens) were used in the microarray assay. To determine the miRNA expression pro les, the miRNA library was constructed with the Agilent "Human microRNA Microarray Kit (v3)" (G4470C, Agilent Technologies, Santa Clara, CA, USA), as described previously [12]. Hierarchical clustering was carried out to show the distinguishable miRNA expression patterns among the samples.…”

Section: Microarray Analysis and Validation By Qrt-pcr Of Differentially Expressed Mirnasmentioning

confidence: 99%

Integrated microRNA Analysis Identifies miR-512-3p as a Potential Biomarker of Poor Outcome in Pediatric Medulloblastoma

Correia

Chagas

Baroni

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

Background: Medulloblastoma, a genetically heterogeneous tumor, is the most frequent malignant brain tumor in children. Although several studies have been carried out, the molecular mechanism underlying medulloblastoma tumorigenesis is not completely known. microRNA (miRNA) expression profiles have been associated with development, progression, and prognosis of human cancers, including medulloblastoma. However, the role of miRNAs in pediatric medulloblastoma has been poorly explored.Methods: Global miRNA expression in 24 microdissected medulloblastoma specimens (19 pediatric and 5 adult specimens) was evaluated by microarray assay. miR-512-3p, the most differentially expressed miRNA in these two groups, was analyzed by qRT-PCR in a cohort of 51 consecutive pediatric medulloblastoma samples and 7 pediatric non-neoplastic cerebellum control samples, and its clinical significance was assessed. Further in silico miRNA prediction of target genes was performed with bioinformatics tools.Results: Compared to the controls, miR-512-3p was significantly downregulated in the pediatric medulloblastoma samples. Higher miR-512-3p was associated with incomplete degree of resection, high risk group classification, and poor overall survival. In silico analysis in an independent cohort of medulloblastoma identified that some of the miR-512-3p target genes (SMAD9, SSX2IP, MAPK10, PTCH1, CCDC6, and BMPR2) were statistically correlated with overall survival, metastasis, and death.Conclusions: For the first time, our results have shown that miR-512-3p is significantly associated with poor clinical outcome in pediatric medulloblastoma, suggesting that miR-512-3p is a potential biomarker of prognosis.

show abstract

“…In particular, those miRNAs that are upregulated in cancer and cause down-regulation of target tumor suppressor mRNAs are defined as “oncomiRNAs” and “metastamiRNAs” [ 25 ]. Concerning GBM, a possible microRNA target is miR-10b-5p [ 26 , 27 , 28 , 29 , 30 , 31 ]. There is, in fact, strong evidence that miR-10b-5p is overexpressed in malignant glioma and associated with tumor invasive factors [ 26 , 27 , 29 ] and GBM aggressiveness [ 31 ].…”

Section: Introductionmentioning

confidence: 99%

“…Concerning GBM, a possible microRNA target is miR-10b-5p [ 26 , 27 , 28 , 29 , 30 , 31 ]. There is, in fact, strong evidence that miR-10b-5p is overexpressed in malignant glioma and associated with tumor invasive factors [ 26 , 27 , 29 ] and GBM aggressiveness [ 31 ]. Importantly, miR-10b-5p is not expressed (or expressed at very low levels) in non-cancerous brain tissues [ 27 ].…”

Section: Introductionmentioning

confidence: 99%

Synergistic Effects of A Combined Treatment of Glioblastoma U251 Cells with An Anti-miR-10b-5p Molecule and An AntiCancer Agent Based on 1-(3′,4′,5′-Trimethoxyphenyl)-2-Aryl-1H-Imidazole Scaffold

Zurlo

Romagnoli

Oliva

et al. 2022

IJMS

View full text Add to dashboard Cite

(1) Background: In the development of new and more effective anticancer approaches, combined treatments appear of great interest. Combination therapy could be of importance in the management of glioblastoma (GBM), a lethal malignancy that accounts for 42% of cancer of the central nervous system, with a median survival of 15 months. This study aimed to verify the activity on a glioblastoma cancer cell line of one of the most active compounds of a novel series of tubulin polymerization inhibitors based on the 1-(3′,4′,5′-trimethoxyphenyl)-2-aryl-1H-imidazole scaffold, used in combination with a miRNA inhibitor molecule targeting the oncomiRNA miR-10b-5p. This microRNA was selected in consideration of the role of miR-10b-5p on the onset and progression of glioblastoma. (2) Methods: Apoptosis was analyzed by Annexin-V and Caspase 3/7 assays, efficacy of the anti-miR-10b-5p was assessed by determining the miR-10b-5p content by RT-qPCR. (3) Results: The results obtained show that a “combination therapy” performed by combining the use of an anti-miR-10b-5p and a 1-(3′,4′,5′-trimethoxyphenyl)-2-aryl-1H-imidazole derivative is an encouraging strategy to boost the efficacy of anticancer therapies and at the same time to reduce side effects.

show abstract

High-throughput microRNA profile in adult and pediatric primary glioblastomas: the role of miR-10b-5p and miR-630 in the tumor aggressiveness

Cited by 7 publications

References 48 publications

MicroRNA expression profile predicts prognosis of pediatric adrenocortical tumors

MicroRNA expression profile predicts prognosis of pediatric adrenocortical tumors

Integrated microRNA Analysis Identifies miR-512-3p as a Potential Biomarker of Poor Outcome in Pediatric Medulloblastoma

Synergistic Effects of A Combined Treatment of Glioblastoma U251 Cells with An Anti-miR-10b-5p Molecule and An AntiCancer Agent Based on 1-(3′,4′,5′-Trimethoxyphenyl)-2-Aryl-1H-Imidazole Scaffold

Contact Info

Product

Resources

About